Krystal Biotech resumed with a Buy at Goldman Sachs
Upside potential from analyst upgrade.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Upside potential from analyst upgrade.
What happened, with direct paths to the underlying reporting
Goldman Sachs targets $441; current price about $341.75.
Target: $441
Posted price: $341.75
Analyst firm: Goldman Sachs
Analyst: Andrea Newkirk
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.